Sana Biotechnology Inc

NASDAQ:SANAUnited States

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Contact Information

Headquarters

188 East Blaine Street, Suite 400SEATTLE, WA, United States 98102

Phone

206-701-7914

Fax

302-636-5454

Executives

Independent Chairman of the Board

Hans Bishop

President, Chief Executive Officer

Steven Harr

Vice Chairman of the Board and Head of SanaX

Richard Mulligan

Chief Financial Officer, Executive Vice President

Nathan Hardy

Executive Vice President, General Counsel, Company Secretary

Bernard Cassidy